載入...
Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?
OBJECTIVE: Bevacizumab is an important component in the treatment of various cancers, and despite guidelines recommending its use in both ovarian and cervical cancer, patient access to bevacizumab and other angiogenesis inhibitors is limited. Biosimilars are large, structurally complex molecules tha...
Na minha lista:
| 發表在: | Gynecol Oncol Res Pract |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5361700/ https://ncbi.nlm.nih.gov/pubmed/28344818 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40661-017-0045-x |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|